Using low molecular weight heparin (LMWH) for prophylaxis and treatment of venous thrombosis offers many advantages over regular heparin. There is no need for use of intravenous pumps, collection and analysis of multiple blood samples for measurement of activated partial thromboplastin time (aPTT), or dose adjustments and manipulations. Eliminating the need for these processes significantly decreases the risk of errors and adverse events. Further, patients can be discharged with LMWH while they are being converted to Coumadin for long-term anticoagulation therapy, which shortens their hospital stay.